Endolymphatic hydrops perspectives 2012

Curr Opin Otolaryngol Head Neck Surg. 2012 Oct;20(5):416-9. doi: 10.1097/MOO.0b013e328357a6c8.

Abstract

Purpose of review: Endolymphatic hydrops remains a significant cause of morbidity secondary to vertigo, hearing loss, and tinnitus. The purpose of this report is to summarize the most clinically relevant publications on endolymphatic hydrops over the past 2 years.

Recent findings: Hydrops has historically been a diagnosis of exclusion, but recent efforts has shown a role for MRI with intratympanic gadolinium. Cochrane reviews of intratympanic dexamethasone and gentamicin found inadequate level 1 evidence to support their use.

Summary: High-level evidence to guide therapy is lacking. MRI holds potential for definitive diagnosis.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Contrast Media
  • Endolymphatic Hydrops / complications
  • Endolymphatic Hydrops / diagnosis*
  • Female
  • Follow-Up Studies
  • Hearing Loss, Sensorineural / drug therapy
  • Hearing Loss, Sensorineural / etiology
  • Hearing Loss, Sensorineural / physiopathology*
  • Humans
  • Image Enhancement / methods
  • Magnetic Resonance Imaging / methods
  • Male
  • Meniere Disease / drug therapy
  • Meniere Disease / etiology
  • Meniere Disease / physiopathology*
  • Risk Assessment
  • Tinnitus / drug therapy
  • Tinnitus / etiology
  • Tinnitus / physiopathology*
  • Treatment Outcome
  • Vertigo / drug therapy
  • Vertigo / etiology
  • Vertigo / physiopathology*

Substances

  • Adrenal Cortex Hormones
  • Anti-Bacterial Agents
  • Contrast Media